Biodesix Secures U.S. Patent for Proprietary Blood Specimen Collection Device
BOULDER, Colo.--(BUSINESS WIRE)--Oct 3, 2019--
Biodesix, Inc., today announced it has been issued U.S. Patent Number 10,422,729, which covers the Biodesix Collection Device (BCD). The new device offers improved ease of use in blood sample collection for diagnostic testing, compared to current standard methods.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191003005237/en/
The Biodesix Collection Device (Photo: Business Wire)
“This device is intuitive and very easy to use,” remarked Susan Garwood, M.D., Pulmonary and Advanced Bronchoscopy Lung Cancer Specialist with Centennial Medical Center in Nashville, part of the HCA TriStar division. “The Biodesix Collection Device enables the opportunity for a fast, simple collection process. Enhancing patient comfort while retaining accuracy is of top concern for all professionals drawing patient blood samples.”
The BCD, currently in use with the Biodesix Nodify XL2™ test, replaces the need for processing samples used for proteomic testing on-site and shipping blood tubes, which often requires cold-chain logistics during transit to the testing laboratory. This reduces the need for processing equipment such as centrifuges in the clinic, improves sample stability during transit and eliminates the need for single-use, bulky shipping containers containing materials such as Styrofoam that are not only costly but also have a negative environmental impact.
“The BCD is designed for exceptional laboratory test performance and surpasses similar collection methods by combining multiple sample processing steps, including specimen collection and reproducible sample separation with ambient shipping. Specimen stability has been demonstrated with analytic measures of proteins using highly sensitive mass spectrometry methods,” said Gary Pestano, Ph.D., chief development officer at Biodesix.
“Our commitment to innovation continues to improve the customer experience,” commented Scott Hutton, chief operating officer at Biodesix. “We are as focused as ever on supporting healthcare professionals and their patients by providing increasingly valuable information to physicians using a noninvasive blood collection. The new BCD significantly reduces cost and environmental impact over current sample collection practices, and we are excited to not only use this for our own tests but to make it available for broad use across the industry.”
Biodesix is planning to use the new BCD in all current and future proteomic testing and also make the device available for purchase by labs and diagnostic companies wishing to use this novel technology for their own sample processing and testing. To see how the BCD is used to collect specimens for the Nodify XL2 test visit this link.
Biodesix is a lung cancer diagnostic solutions company addressing the continuum of patient care from early diagnosis of lung nodules through late stage cancer. The company develops diagnostic tests addressing important clinical questions by combining simple blood draws and multi-omics with the power of artificial intelligence. Biodesix is the first company to offer three best-in class tests for patients with lung cancer, and multiple pipeline tests including one with the potential to identify patients who may benefit from immunotherapies. The Biodesix Lung Reflex ® strategy integrates the GeneStrat ® and VeriStrat ® tests to support treatment decisions with results in 72 hours. The Nodify XL2™ nodule test evaluates the risk of malignancy, enabling physicians to triage patients to the most appropriate course of action. Biodesix also partners with the world’s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges. For more information about Biodesix, please visit www.biodesix.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20191003005237/en/
CONTACT: Kena Hudson for Biodesix
KEYWORD: COLORADO UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH GENERAL HEALTH MEDICAL DEVICES HOSPITALS
SOURCE: Biodesix, Inc.
Copyright Business Wire 2019.
PUB: 10/03/2019 08:00 AM/DISC: 10/03/2019 08:01 AM